Climate change and global warming resulting from greenhouse gas emissions are widely recognized as the biggest threats to global health. The healthcare sector is responsible for 4–5% of global emissions, more than 70% of which are driven by supply chains.
Viewing related articles
This paper summarizes the industry position and aims to start a strategic discussion on this situation. It will help ensure we have a common language and understanding across industry. Looking ahead, we will emphasize shared learning, best practices, and retrospective investigations to improve long-range planning processes
This paper proposes that shared and electronic data exchange (EDE) is a cornerstone of collaboration and innovation in the supply chain. The paper aims to demystify EDE, set out its importance for supply chain effectiveness, capture its benefits and help people understand the practical enablers.
This paper provides an overview of the current and near-future bioprocess supply situation and trends. This research provides insights into how the industry has adjusted as the Pandemic begins to abate.
This template allows suppliers and customers to exchange the right information at the right time and helpa standardize this function and ensure that the ‘minimal required information’ is created and shared.
This paper provides an introduction and a high-level view of on time in full (OTIF) so that when we use the acronym, we know how it is calculated and are all using it in the same way. It examines detail on the components of ‘Actual orders delivered’ and ‘Expected orders to be delivered’ and talks about the information included, actions to take and gives tips on how to best use each component.
Jun 2022 | Cell & Gene Therapy, COVID 19, Deliverable, Deliverables Report, Development Group, Drug Substance, Fill Finish, Information Technology, Inline Monitoring and Realtime Release, Publication, Supply Partner, Technology Roadmapping
Historically, the biopharmaceutical industry has relied on traditional pharmaceutical manufacturing practices to make and release products. This publication examines the future of biopharmaceutical manufacturing by presenting the vision of fully implemented in-line monitoring (ILM) and real-time release. This aspirational vision includes full ILM, predictive analytics and advanced process controls (APC) enabling release of product in real time, with concomitant predictive and preventative alerts and resolution of process, equipment and other production issues.
These tools support sharing the optimal high-level steps to simplify a process and invite people into the discussion using a common language. The optimal process outlines the essential process steps and for each one lists the ‘who’ (i.e., which role) and the ‘how’ (i.e., what medium). The RACI supports people to understand where accountabilities and responsibilities lie.
Suite of deliverables to support the forecast and demand planning process and complement the FDP Toolkit. They include an optimal process, RACI and template. These areas are where there is potential for the greatest benefit and will create value for industry when used correctly.
BioPhorum response to USP <1083> draft monograph: Supplier qualification and guidance for associated risk assessments
BioPhorum member only content. This is detailed consultation response from BioPhorum Supply Partner to USP on draft monograph <1083>.